<DOC>
	<DOCNO>NCT01467713</DOCNO>
	<brief_summary>The purpose study determine efficacy safety ramelteon , nightly bedtime ( QHS ) , sublingual ( SL ) , maintenance treatment Bipolar I Disorder adult patient .</brief_summary>
	<brief_title>Efficacy Safety Ramelteon Sublingual Adjunctive Therapy Maintenance Treatment Bipolar I Disorder</brief_title>
	<detailed_description>TAK-375SL ( ramelteon sublingual formulation ) develop Takeda Pharmaceutical Company Limited adjunctive treatment maintenance therapy bipolar I disorder . Participants see twice month first two month every month end 9-month treatment period . Participants complete 9-month treatment period follow-up visit approximately seven day last visit . A safety followup phone call make 30 day completion 9-month treatment period . Based recommendation Independent Data Monitoring Committee determine study data meet pre-determined criterion futility , Takeda make decision terminate study . No safety concern identify Independent Data Monitoring Committee</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<criteria>1 . In opinion investigator , participant capable understand comply protocol requirement . 2 . The participant , applicable , participant 's legally acceptable representative sign date write , informed consent form require privacy authorization prior initiation study procedure . 3 . The participant suffers bipolar I disorder , accord Diagnostic Statistical Manual Mental Disorders , Fourth Edition , Text Revision ( DSMIVTR ) criterion confirm Structured Clinical Interview DSM Disorders ( SCID ) . 4 . The participant man woman age 18 75 year , inclusive . 5 . The participant identify caregiver person responsible ( e.g . family member , spouse , case worker nurse residential living ( facility ) consider reliable investigator . 6 . The recent mood episode ( depression , mania , mixed episode ) within past 9 month screen . 7 . The participant remission opinion principal investigator ( PI ) least 8 week prior baseline recent mood episode . 8 . The participant MontgomeryÅsberg Depression Rating Scale ( MADRS ) total score ≤12 Screening Baseline visit . 9 . The participant Young Mania Rating Scale ( YMRS ) score ≤10 Screening Baseline visit . 10 . The participant Clinical Global Impression Scale Severity ( CGIS ) score ≤2 Screening Baseline visit . 11 . Hamilton Rating Scale Anxiety ( HAMA ) score ≤21 Screening Baseline visit . 12 . The participant 's medication bipolar I disorder stable i.e. , dose adjustment make least 8 week prior randomization 13 . A male participant nonsterilized sexually active female partner childbearing potential agrees use adequate contraception signing informed consent duration study 30 day last dose . 14 . A female participant childbearing potential sexually active non sterilize male partner agree use routinely adequate contraception signing inform consent throughout duration study 30 day last dose . 1 . The participant receive investigational compound &lt; 30 day Screening 5 halflives prior Screening . 2 . The participant ever receive ramelteon previous clinical study ever use ramelteon . 3 . The participant immediate family member , study site employee , dependent relationship study site employee involve conduct study ( eg , spouse , parent , child , sibling ) may consent duress . 4 . The participant one following : Any current psychiatric disorder primary focus treatment bipolar I disorder defined DSMIVTR , assess SCID . Current history : schizophrenia psychotic disorder , include major depression psychotic feature , bipolar depression psychotic feature ( exception psychosis associate manic mixed episode ) , obsessivecompulsive disorder ( OCD ) , mental retardation , organic mental disorder , mental disorder due general medical condition define DSMIVTR . Current diagnosis history alcohol substance abuse ( exclude nicotine caffeine ) define DSMIVTR full sustain remission three month day screen ( Participant must also negative urine drug screen Screening Baseline ; exception benzodiazepine opiates provided participant valid prescription ) . Current diagnosis history alcohol substance dependence ( exclude nicotine caffeine ) define DSMIVTR full sustain remission six month day screen . ( Participant must also negative urine drug screen Screening Baseline ; exception benzodiazepine opiates provided participant valid prescription ) . Presence history clinically significant neurological disorder ( include epilepsy ) determine investigator . Neurodegenerative disorder ( Alzheimer disease , Parkinson disease , multiple sclerosis , Huntington disease , etc ) . Any Axis II disorder might compromise study . History Rapid Cycling bipolar disorder : Patients 8 episode mood disorder per year . 5 . The participant experience first episode mood disorder age 65 year . 6 . The participant medication antidepressant ( except fluvoxamine ) , mood stabilizer ( lithium , valproate , lamotrigine ) , atypical antipsychotic ( risperidone , lithium and/or valproate , level specify range : lithium ( serum level 1.2 mEq/L ) ; valproate ( serum level 125 mcg/ml ) screening . 7 . The participant receive electroconvulsive therapy , vagal nerve stimulation , repetitive transcranial magnetic stimulation within 6 month prior Screening . 8 . The participant start receive formal cognitive behavioral therapy , systematic psychotherapy within 30 day screen plan initiate therapy study ( supportive therapy , marital therapy bereavement counsel allow ) . 9 . The participant significant risk suicide accord investigator 's clinical judgment score ≥5 item 10 ( suicidal thought ) MADRS make suicide attempt previous 6 month . 10 . The participant require take excluded medication anticipate participant require treatment least 1 disallow concomitant medication study . 11 . The participant clinically significant unstable illness , example hepatic impairment renal insufficiency , cardiovascular , pulmonary , gastrointestinal , endocrine , neurological , rheumatologic , immunologic , hematological , infectious , dermatological disorder metabolic disturbance . 12 . The participant history current diagnosis Fibromyalgia , Chronic Fatigue Syndrome , Chronic Pain Syndrome Sleep apnea . 13 . The participant previous history cancer remission le 5 year prior first dose study medication . This criterion include participant basal cell stage I squamous cell carcinoma skin . 14 . The participant 1 laboratory value outside normal range , base blood urine sample take Screening Visit , consider investigator clinically significant ; participant follow value Screening Visit : A serum creatinine value &gt; 1.5 time upper limit normal ( xULN ) . A serum total bilirubin value &gt; 1.5 xULN . A serum alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) value &gt; 2 xULN . 15 . The participant glycosylated hemoglobin ( HbA1C ) ≥7 % screen prior diagnosis diabetes and/or treatment diabetes . NOTE : Participants know diabetes exclude . 16 . The participant thyroid stimulate hormone ( TSH ) value outside normal range Screening Visit deem clinically significant investigator . NOTE : T4 check TSH range . If T4 abnormal participant exclude . 17 . The participant clinically significant abnormal vital sign determine investigator . 18 . The participant abnormal electrocardiogram determine central reader confirm clinically significant investigator . 19 . The participant disease take medication , opinion investigator , could interfere assessment safety , tolerability , efficacy . 20 . The participant positive urine drug screen . NOTE : Positive urine drug screen benzodiazepine opiate participant valid prescription allow . 21 . The participant disease take medication , opinion investigator , could interfere assessment safety , tolerability , efficacy . 22 . The participant positive urine drug screen . NOTE : Positive urine drug screen benzodiazepine opiate participant valid prescription allow . 23 . The participant , opinion investigator , unlikely comply clinical study protocol unsuitable reason .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Drug Therapy</keyword>
</DOC>